TY - JOUR AU - Arima Hisatomi AU - Matsushita K. AU - Ballew S. AU - Ohkubo T. AU - Ishani A. AU - Djurdjev O. AU - Stengel B. AU - Cirillo M. AU - Shankar A. AU - Sang Y. AU - Iseki K. AU - Appel L. AU - Chadban S. AU - Coresh J. AU - Turin T. AU - Green J. AU - Heine G. AU - Inker L. AU - Irie F. AU - Ix J. AU - Kovesdy C. AU - Marks A. AU - Shalev V. AU - Wen C. AU - de Jong P. AB -

IMPORTANCE The established chronic kidney disease (CKD) progression end point of end-stage renal disease (ESRD) or a doubling of serum creatinine concentration (corresponding to a change in estimated glomerular filtration rate [GFR] of -57% or greater) is a late event. OBJECTIVE To characterize the association of decline in estimated GFR with subsequent progression to ESRD with implications for using lesser declines in estimated GFR as potential alternative end points for CKD progression. Because most people with CKD die before reaching ESRD, mortality risk also was investigated. DATA SOURCES AND STUDY SELECTION Individual meta-analysis of 1.7 million participants with 12 344 ESRD events and 223 944 deaths from 35 cohorts in the CKD Prognosis Consortium with a repeated measure of serum creatinine concentration over 1 to 3 years and outcome data. DATA EXTRACTION AND SYNTHESIS Transfer of individual participant data or standardized analysis of outputs for random-effects meta-analysis conducted between July 2012 and September 2013, with baseline estimated GFR values collected from 1975 through 2012. MAIN OUTCOMES AND MEASURES End-stage renal disease (initiation of dialysis or transplantation) or all-cause mortality risk related to percentage change in estimated GFR over 2 years, adjusted for potential confounders and first estimated GFR. RESULTS The adjusted hazard ratios (HRs) of ESRD and mortality were higher with larger estimated GFR decline. Among participants with baseline estimated GFR of less than 60 mL/min/1.73 m2, the adjusted HRs for ESRD were 32.1 (95% CI, 22.3-46.3) for changes of -57% in estimated GFR and 5.4 (95% CI, 4.5-6.4) for changes of -30%. However, changes of -30% or greater (6.9% [95% CI, 6.4%-7.4%] of the entire consortium) were more common than changes of -57% (0.79% [95% CI, 0.52%-1.06%]). This association was strong and consistent across the length of the baseline period (1 to 3 years), baseline estimated GFR, age, diabetes status, or albuminuria. Average adjusted 10-year risk of ESRD (in patients with a baseline estimated GFR of 35 mL/min/1.73 m2) was 99% (95% CI, 95%-100%) for estimated GFR change of -57%, was 83% (95% CI, 71%-93%) for estimated GFR change of -40%, and was 64% (95% CI, 52%-77%) for estimated GFR change of -30% vs 18% (95% CI, 15%-22%) for estimated GFR change of 0%. Corresponding mortality risks were 77% (95% CI, 71%-82%), 60% (95% CI, 56%-63%), and 50% (95% CI, 47%-52%) vs 32% (95% CI, 31%-33%), showing a similar but weaker pattern. CONCLUSIONS AND RELEVANCE Declines in estimated GFR smaller than a doubling of serum creatinine concentration occurred more commonly and were strongly and consistently associated with the risk of ESRD and mortality, supporting consideration of lesser declines in estimated GFR (such as a 30% reduction over 2 years) as an alternative end point for CKD progression.

AD - Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Johns Hopkins Medical Institutions, Baltimore, Maryland.
George Institute for Global Health, University of Sydney, Sydney, Australia.
Department of Nephrology and Transplantation, Royal Prince Alfred Hospital, Sydney, Australia6Sydney Medical School, University of Sydney, Sydney, Australia.
Department of Medicine, University of Salerno, Salerno, Italy.
BC Provincial Renal Agency, Vancouver, British Columbia, Canada.
Nephrology Department, Geisinger Medical Center, Danville, Pennsylvania.
Department of Internal Medicine IV, Nephrology, and Hypertension, Saarland University Medical Center, Hamburg, Germany.
Division of Nephrology, Tufts Medical Center, Boston, Massachusetts.
Department of Health and Welfare, Ibaraki Prefectural Office, Mito, Japan.
Minneapolis VA Health Care System and Department of Medicine, University of Minnesota, Minneapolis.
University of California, San Diego.
Memphis Veterans Affairs Medical Center, Memphis, Tennessee16University of Tennessee Health Science Center, Memphis.
Division of Applied Health Sciences, University of Aberdeen, and NHS Grampian, Aberdeen, Scotland.
Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan19Department of Planning for Drug Development and Clinical Evaluation, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai, Japan20Department of He.
Medical Informatics Department, Maccabi Healthcare Services, and Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Family Medicine and Population Health, Virginia Commonwealth University School of Medicine, Richmond.
China Medical University Hospital, Taichung, Taiwan24Institute of Population Health Science, National Health Research Institutes, Zhunan, Taiwan.
Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Dialysis Unit, University Hospital of the Ryukyus, Okinawa, Japan.
Inserm U1018, CESP Center for Research in Epidemiology and Population Health and UMRS 1018, Paris-Sud University, Villejuif, France. AN - 24892770 BT - Journal of the American Medical Association DA - 29691111715 DP - NLM ET - 2014/06/04 LA - Eng LB - NMH N1 - Coresh, Josef
Turin, Tanvir Chowdhury
Matsushita, Kunihiro
Sang, Yingying
Ballew, Shoshana H
Appel, Lawrence J
Arima, Hisatomi
Chadban, Steven J
Cirillo, Massimo
Djurdjev, Ognjenka
Green, Jamie A
Heine, Gunnar H
Inker, Lesley A
Irie, Fujiko
Ishani, Areef
Ix, Joachim H
Kovesdy, Csaba P
Marks, Angharad
Ohkubo, Takayoshi
Shalev, Varda
Shankar, Anoop
Wen, Chi Pang
de Jong, Paul E
Iseki, Kunitoshi
Stengel, Benedicte
Gansevoort, Ron T
Levey, Andrew S
for the CKD Prognosis Consortium
JAMA. 2014 Jun 3. doi: 10.1001/jama.2014.6634. N2 -

IMPORTANCE The established chronic kidney disease (CKD) progression end point of end-stage renal disease (ESRD) or a doubling of serum creatinine concentration (corresponding to a change in estimated glomerular filtration rate [GFR] of -57% or greater) is a late event. OBJECTIVE To characterize the association of decline in estimated GFR with subsequent progression to ESRD with implications for using lesser declines in estimated GFR as potential alternative end points for CKD progression. Because most people with CKD die before reaching ESRD, mortality risk also was investigated. DATA SOURCES AND STUDY SELECTION Individual meta-analysis of 1.7 million participants with 12 344 ESRD events and 223 944 deaths from 35 cohorts in the CKD Prognosis Consortium with a repeated measure of serum creatinine concentration over 1 to 3 years and outcome data. DATA EXTRACTION AND SYNTHESIS Transfer of individual participant data or standardized analysis of outputs for random-effects meta-analysis conducted between July 2012 and September 2013, with baseline estimated GFR values collected from 1975 through 2012. MAIN OUTCOMES AND MEASURES End-stage renal disease (initiation of dialysis or transplantation) or all-cause mortality risk related to percentage change in estimated GFR over 2 years, adjusted for potential confounders and first estimated GFR. RESULTS The adjusted hazard ratios (HRs) of ESRD and mortality were higher with larger estimated GFR decline. Among participants with baseline estimated GFR of less than 60 mL/min/1.73 m2, the adjusted HRs for ESRD were 32.1 (95% CI, 22.3-46.3) for changes of -57% in estimated GFR and 5.4 (95% CI, 4.5-6.4) for changes of -30%. However, changes of -30% or greater (6.9% [95% CI, 6.4%-7.4%] of the entire consortium) were more common than changes of -57% (0.79% [95% CI, 0.52%-1.06%]). This association was strong and consistent across the length of the baseline period (1 to 3 years), baseline estimated GFR, age, diabetes status, or albuminuria. Average adjusted 10-year risk of ESRD (in patients with a baseline estimated GFR of 35 mL/min/1.73 m2) was 99% (95% CI, 95%-100%) for estimated GFR change of -57%, was 83% (95% CI, 71%-93%) for estimated GFR change of -40%, and was 64% (95% CI, 52%-77%) for estimated GFR change of -30% vs 18% (95% CI, 15%-22%) for estimated GFR change of 0%. Corresponding mortality risks were 77% (95% CI, 71%-82%), 60% (95% CI, 56%-63%), and 50% (95% CI, 47%-52%) vs 32% (95% CI, 31%-33%), showing a similar but weaker pattern. CONCLUSIONS AND RELEVANCE Declines in estimated GFR smaller than a doubling of serum creatinine concentration occurred more commonly and were strongly and consistently associated with the risk of ESRD and mortality, supporting consideration of lesser declines in estimated GFR (such as a 30% reduction over 2 years) as an alternative end point for CKD progression.

PY - 2014 SN - 1538-3598 (Electronic) - 0098-7484 (Linking) T2 - Journal of the American Medical Association TI - Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality ER -